These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 18565985)

  • 1. Contaminant in the recalled unfractionated heparin preparations: where is the problem?
    Hoppensteadt DA; Wahi R; Adiguzel C; Iqbal O; Ramacciotti E; Bick RL; Messmore HL; Bansal V; Fareed J
    Clin Appl Thromb Hemost; 2008 Jul; 14(3):261-6. PubMed ID: 18565985
    [No Abstract]   [Full Text] [Related]  

  • 2. Lessons from contaminated heparin.
    Dodd S; Besag FM
    Curr Drug Saf; 2009 Jan; 4(1):1. PubMed ID: 19149518
    [No Abstract]   [Full Text] [Related]  

  • 3. The tainted heparin story: an update.
    Guerrini M; Shriver Z; Bisio A; Naggi A; Casu B; Sasisekharan R; Torri G
    Thromb Haemost; 2009 Nov; 102(5):907-11. PubMed ID: 19888527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in the USP heparin monograph and implications for clinicians.
    Smythe MA; Nutescu EA; Wittkowsky AK
    Pharmacotherapy; 2010 May; 30(5):428-31. PubMed ID: 20411994
    [No Abstract]   [Full Text] [Related]  

  • 5. Tainted heparin crisis tested FDA's investigative skills.
    Lavine G
    Am J Health Syst Pharm; 2009 Feb; 66(3):210-1. PubMed ID: 19179633
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulators scramble to tighten loopholes after heparin debacle.
    Jia H
    Nat Biotechnol; 2008 May; 26(5):477-8. PubMed ID: 18464756
    [No Abstract]   [Full Text] [Related]  

  • 7. Description of hypersensitivity adverse events following administration of heparin that was potentially contaminated with oversulfated chondroitin sulfate in early 2008.
    McMahon AW; Pratt RG; Hammad TA; Kozlowski S; Zhou E; Lu S; Kulick CG; Mallick T; Dal Pan G
    Pharmacoepidemiol Drug Saf; 2010 Sep; 19(9):921-33. PubMed ID: 20661880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Contaminated heparins].
    Monneret C
    Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From crisis to opportunity: a perspective on the heparin crisis.
    Sasisekharan R; Shriver Z
    Thromb Haemost; 2009 Nov; 102(5):854-8. PubMed ID: 19888519
    [No Abstract]   [Full Text] [Related]  

  • 10. Heparin-focus on safety.
    Golembiewski J
    J Perianesth Nurs; 2008 Aug; 23(4):276-8. PubMed ID: 18657765
    [No Abstract]   [Full Text] [Related]  

  • 11. Hemodialysis patients' deaths in the USA by contaminant suspected heparin originating from China.
    Nosé Y
    Artif Organs; 2008 Jun; 32(6):425-6. PubMed ID: 18522553
    [No Abstract]   [Full Text] [Related]  

  • 12. Contaminated heparin preparations, severe adverse events and the contact system.
    Ramacciotti E; Wahi R; Messmore HL
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):489-91. PubMed ID: 18815138
    [No Abstract]   [Full Text] [Related]  

  • 13. Adulteration of drugs and foods: compendial approaches to lowering risk.
    Abernethy DR; Sheehan C; Griffiths JC; Williams RL;
    Clin Pharmacol Ther; 2009 Apr; 85(4):444-7. PubMed ID: 18463621
    [No Abstract]   [Full Text] [Related]  

  • 14. Product-related adverse events in hemodialysis patients: improving recognition and response.
    Patel PR; Kallen AJ; Budnitz DS
    Am J Kidney Dis; 2010 May; 55(5):972; author reply 973. PubMed ID: 20438988
    [No Abstract]   [Full Text] [Related]  

  • 15. Multistate outbreak of Serratia marcescens bloodstream infections caused by contamination of prefilled heparin and isotonic sodium chloride solution syringes.
    Blossom D; Noble-Wang J; Su J; Pur S; Chemaly R; Shams A; Jensen B; Pascoe N; Gullion J; Casey E; Hayden M; Arduino M; Budnitz DS; Raad I; Trenholme G; Srinivasan A;
    Arch Intern Med; 2009 Oct; 169(18):1705-11. PubMed ID: 19822828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolation and characterization of contaminants in recalled unfractionated heparin and low-molecular-weight heparin.
    Viskov C; Bouley E; Hubert P; Martinez C; Herman F; Jeske W; Hoppensteadt D; Walenga JM; Fareed J
    Clin Appl Thromb Hemost; 2009; 15(4):395-401. PubMed ID: 19617248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contaminated antiseptic products recalled.
    FDA Consum; 2000; 34(4):5. PubMed ID: 11924637
    [No Abstract]   [Full Text] [Related]  

  • 18. [Artificial polysaccharide in contaminated heparin. Acute hypersensitivity reactions explained--but how could it happen?].
    Lindahl U
    Lakartidningen; 2008 Sep 24-30; 105(39):2660-1. PubMed ID: 18846871
    [No Abstract]   [Full Text] [Related]  

  • 19. Sales of contaminated animal drugs halted.
    Henkel J
    FDA Consum; 1999; 33(5):34. PubMed ID: 10522171
    [No Abstract]   [Full Text] [Related]  

  • 20. The US regulatory and pharmacopeia response to the global heparin contamination crisis.
    Szajek AY; Chess E; Johansen K; Gratzl G; Gray E; Keire D; Linhardt RJ; Liu J; Morris T; Mulloy B; Nasr M; Shriver Z; Torralba P; Viskov C; Williams R; Woodcock J; Workman W; Al-Hakim A
    Nat Biotechnol; 2016 Jun; 34(6):625-30. PubMed ID: 27281424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.